

RESEARCH

Open Access



Prediction of noninvasive ventilation failure using the ROX index in patients with de novo acute respiratory failure

Jun Duan^{1†}, Juhua Yang^{2†}, Lei Jiang¹, Linfu Bai¹, Wenhui Hu¹, Weiwei Shu³, Ke Wang⁴ and Fuxun Yang^{5*}

Abstract

Background: The ratio of SpO₂/FiO₂ to respiratory rate (ROX) index is commonly used to predict the failure of high-flow nasal cannula. However, its predictive power for noninvasive ventilation (NIV) failure is unclear.

Methods: This was a secondary analysis of a multicenter prospective observational study, intended to update risk scoring. Patients with de novo acute respiratory failure were enrolled, but hypercapnic patients were excluded. The ROX index was calculated before treatment and after 1–2, 12, and 24 h NIV. Differences in predictive power for NIV failure using the ROX index, PaO₂/FiO₂, and PaO₂/FiO₂/respiratory rate were tested.

Results: A total of 1286 patients with de novo acute respiratory failure were enrolled. Of these, 568 (44%) experienced NIV failure. Patients with NIV failure had a lower ROX index than those with NIV success. The rates of NIV failure were 92.3%, 70.5%, 55.3%, 41.1%, 35.1%, and 29.5% in patients with ROX index values calculated before NIV of ≤ 2, 2–4, 4–6, 6–8, 8–10, and > 10, respectively. Similar results were found when the ROX index was assessed after 1–2, 12, and 24 h NIV. The area under the receiver operating characteristics curve was 0.64 (95% CI 0.61–0.67) when the ROX index was used to predict NIV failure before NIV. It increased to 0.71 (95% CI 0.68–0.74), 0.74 (0.71–0.77), and 0.77 (0.74–0.80) after 1–2, 12, and 24 h NIV, respectively. The predictive power for NIV failure was similar for the ROX index and for the PaO₂/FiO₂. Likewise, no difference was found between the ROX index and the PaO₂/FiO₂/respiratory rate, except at the time point of 1–2 h NIV.

Conclusions: The ROX index has moderate predictive power for NIV failure in patients with de novo acute respiratory failure.

Keywords: Acute respiratory failure, Noninvasive ventilation, ROX index

Background

The use of noninvasive ventilation (NIV) is common in patients with de novo acute respiratory failure [1]. Its use decreases the odds ratio (OR) of intubation relative to conventional oxygen therapy [2]. However, the rate

of NIV failure is high in this patient population, ranging from 40% to 65% [3–6]. Furthermore, a two- to six-fold greater rate of mortality is seen in patients with NIV failure relative to that in patients with NIV success [7]. Among patients with NIV failure, delayed intubation further increases the risk of death [8, 9]. Early identification of high-risk patients and early application of intubation is a promising strategy for reducing mortality [10].

The ratio of SpO₂/FiO₂ to respiratory rate (ROX) index was developed by Roca et al. [11] to predict the failure of high-flow nasal cannula (HFNC). They showed that the area under the receiver operating characteristics curve

[†]Jun Duan and Juhua Yang contributed equally to the study

*Correspondence: guilian4@163.com

⁵Department of ICU, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W. Sec 2, 1st Ring Rd, Chengdu 610072, China

Full list of author information is available at the end of the article

(AUC) was between 0.66 and 0.80 from initiation to 24 h HFNC when the ROX index was used to predict HFNC failure [12]. The index has also been used to predict HFNC failure in patients with COVID-19 pneumonia [13, 14]. Because measurement of the ROX index is feasible, effective, and reproducible, it is widely used to predict HFNC failure [15, 16]. To the best of our knowledge, the value of the prediction of NIV failure obtained using the ROX index is unclear. Here, we explored the predictive power of the ROX index for NIV failure in patients with de novo acute respiratory failure.

Methods

This was a secondary analysis of a multicenter prospective observational study performed to update HACOR scoring [17]. It was conducted in 18 hospitals in China and Turkey from September 2017 to September 2021. The relevant ethics committees approved the study and informed consent was obtained from the patients or their family members. We enrolled patients with de novo acute respiratory failure. However, hypercapnic patients were excluded. De novo acute respiratory failure was defined as occurrence of respiratory failure without chronic respiratory disease, chronic heart disease, asthma, cardiogenic pulmonary edema, cardiac problems other than cardiogenic pulmonary edema, or postoperative hypoxemia [2–4, 17, 18].

Patients who were admitted to the participating centers were managed by the attending physicians, respiratory therapists, and nurses in charge. NIV was used to avert respiratory failure if the respiratory rate (RR) was >25 breaths/min, if a clinical presentation of breathlessness at rest emerged (such as active contraction of the accessory inspiratory muscles or paradoxical abdominal motion), or PaO₂ fell to <60 mmHg at room air pressure or PaO₂/FiO₂ fell to <300 mmHg with supplemental oxygen [17]. The formula of $21 + 4 \times \text{flow (L/min)}$ was used to estimate the FiO₂ if supplemental oxygen was used [19, 20]. A face mask or nasal mask was used to connect the patient to the ventilator. If NIV intolerance occurred, HFNC was used as an alternative strategy to prevent intubation. NIV intolerance was defined as termination of NIV due to discomfort, even in case of intermittent use [21].

We collected diagnoses and underlying diseases at admission. Pneumonia was assessed as new or increasing pulmonary infiltrate in chest radiographs coupled with clinical findings suggesting infection, such as new onset of fever, purulent sputum, cough, chest pain, leukocytosis, decline in oxygenation, and so on [22]. Acute respiratory distress syndrome (ARDS) was diagnosed as follows: (1) presence of acute hypoxemic respiratory failure with PaO₂/FiO₂ less than 300 mmHg; (2) within 1 week of a

clinical insult or the presence of new (within 7 days) or worsening respiratory symptoms; (3) bilateral opacities in computed tomographic (CT) scans or chest X-rays not fully explained by effusions, lobar or lung collapse, or nodules; and (4) respiratory failure not fully explained by cardiogenic pulmonary edema or fluid overload [23, 24].


Consciousness was assessed using the Glasgow Coma Scale (GCS). GCS, heart rate, RR, blood pressure, pH, PaCO₂, PaO₂/FiO₂, and SpO₂ were collected before treatment and after 1–2, 12, and 24 h NIV. Disease severity was assessed with the sequential organ failure assessment (SOFA) score. The primary outcome was NIV failure, which was defined as the requirement of intubation [17]. The secondary outcomes were duration of ICU stay and duration of hospital stay.

We used MedCalc (MedCalc Software Ltd, Ostend, Belgium) and SPSS (version 25.0; IBM Corp., Armonk, NY) to analyze the data. Normally distributed continuous variables were analyzed using Student's *t* test, and abnormally distributed continuous variables were analyzed using the Mann–Whitney *U* test when appropriate. Categorical variables were analyzed using the chi-squared test or Fisher's exact test, where appropriate. The ability to predict NIV failure was tested with the AUC. The Hanley and McNeil method was used to test the difference in AUC between the ROX index and PaO₂/FiO₂ or between the ROX index and PaO₂/FiO₂/RR [25]. Three cutoff values were selected for clinical reference at probabilities of NIV failure equal to 25%, 50%, and 75% [26]. Patients with probabilities of NIV failure less than 25%, 25–50%, 50–75%, and more than 75% after 1–2 h NIV were termed the low, moderate, high, and very high risk for NIV failure groups, respectively. A *p* value less than 0.05 was considered to indicate statistical significance.

Results

A total of 5413 patients were screened (Fig. 1). In all, 1286 patients were enrolled in the final analysis. Of these, 23 cases (1.8%) had missing data concerning PaO₂ at some time point. The rate of NIV failure was 44% (568/1286). Patients with NIV failure had a higher SOFA score (6.1 ± 2.9 vs. 4.8 ± 2.4 , $p < 0.01$) than those with NIV success (Table 1). They also had higher hospital mortality than successful patients (43% vs. 4%, $p < 0.01$). The PaO₂/FiO₂ values collected before and after 1–2 h NIV were lower in patients with NIV failure than in those with NIV success (145 ± 76 vs. 167 ± 91 mmHg, $p < 0.01$; and 156 ± 82 vs. 213 ± 92 mmHg, $p < 0.01$, respectively). Similar results were found for SpO₂.

In the NIV failure group, the ROX index was much lower than that in the successful NIV group when the index was calculated before NIV (Fig. 2). The rates of NIV failure were 92.3%, 70.5%, 55.3%, 41.1%, 35.1%, and



29.5% in patients with ROX index ≤ 2 , 2–4, 4–6, 6–8, 8–10, and > 10 , respectively (Fig. 3). Similar results were found when the ROX index was assessed after 1–2, 12, and 24 h NIV.

Before NIV, the AUC was 0.64 (95% confidence interval [CI] 0.61–0.67) when the ROX index was used to predict NIV failure (Fig. 4). It increased to 0.71 (95% CI 0.68–0.74), 0.74 (0.71–0.77), and 0.77 (0.74–0.80) when the ROX index was assessed to predict NIV failure after 1–2, 12, and 24 h NIV, respectively. The sensitivity and

specificity to predict NIV failure under different cutoff values of ROX index are presented in Table 2.

After 1–2 h NIV, the probability of NIV failure was 25%, 50%, and 75% for the ROX index cutoff values of 2, 6, and 10, respectively. Patients were classified into low, moderate, high, and very high risk groups for ROX index values of > 10 , 6–10, 2–6, and ≤ 2 , respectively. The rates of NIV failure were 23%, 34.1%, 64.3%, and 100% in these respective groups when the ROX index was used to stratify patients after 1–2 h NIV. Compared to the ROX index

Table 1 Comparisons between patients with NIV success and failure



	NIV success N = 718	NIV failure N = 568	p
Age, years	57 ± 17	60 ± 17	< 0.01
Male	430 (60%)	381 (67%)	< 0.01
SOFA score	4.8 ± 2.4	6.1 ± 2.9	< 0.01
Presence of ARDS	173 (24%)	181 (32%)	< 0.01
Use of vasopressor during NIV	69 (10%)	95 (17%)	< 0.01
Diagnosis			
Pneumonia	362 (50%)	409 (72%)	< 0.01
Nonpulmonary sepsis	108 (15%)	81 (14%)	0.75
Pancreatitis	127 (18%)	37 (7%)	< 0.01
Other	121 (17%)	41 (7%)	< 0.01
Underlying disease			
Hypertension	234 (33%)	165 (29%)	0.18
Diabetes mellitus	153 (21%)	106 (19%)	0.26
Chronic kidney disease	65 (9%)	50 (9%)	0.92
Chronic liver disease	28 (4%)	32 (6%)	0.15
Variables collected before NIV			
GCS	14.7 ± 0.8	14.5 ± 1.5	< 0.01
Heart rate, beats/min	114 ± 24	117 ± 24	0.02
Respiratory rate, breaths/min	30 ± 7	33 ± 8	< 0.01
Systolic blood pressure, mmHg	133 ± 25	129 ± 26	< 0.01
Diastolic blood pressure, mmHg	77 ± 17	76 ± 16	0.19
pH	7.43 ± 0.09	7.42 ± 0.11	0.02
PaCO ₂ , mmHg	33 ± 7	33 ± 8	0.18
PaO ₂ /FiO ₂ , mmHg	167 ± 91	145 ± 76	< 0.01
SpO ₂ , %	90 ± 7	87 ± 9	< 0.01
Variables collected after 1–2 h NIV			
GCS	14.8 ± 0.7	14.5 ± 1.5	< 0.01
Heart rate, beats/min	106 ± 21	111 ± 23	< 0.01
Respiratory rate, breaths/min	26 ± 6	31 ± 8	< 0.01
Systolic blood pressure, mmHg	129 ± 22	126 ± 24	0.03
Diastolic blood pressure, mmHg	74 ± 14	72 ± 14	0.02
pH	7.44 ± 0.07	7.41 ± 0.10	< 0.01
PaCO ₂ , mmHg	33 ± 7	34 ± 12	0.17
PaO ₂ /FiO ₂ , mmHg	213 ± 92	156 ± 82	< 0.01
SpO ₂ , %	97 ± 3	95 ± 5	< 0.01
Outcome			
Death in hospital	28 (4%)	245 (43%)	< 0.01
Length of ICU stay, days	7 (5–12)	8 (4–14)	0.92
Length of hospital stay, days	19 (12–28)	13 (6–24)	< 0.01

NIV noninvasive ventilation, ARDS acute respiratory distress syndrome, SOFA sequential organ failure assessment, GCS Glasgow coma scale

before NIV, improved patients had lower rates of NIV failure than the deteriorated patients after 1–2, 12, and 24 h NIV (Fig. 5).

ROX index values had similar AUCs to PaO₂/FiO₂ when NIV failure was predicted within 24 h NIV

(Table 3). Compared to PaO₂/FiO₂/RR, the ROX index also had similar AUCs before NIV and after 12 and 24 h NIV. Only after 1–2 h NIV was the AUC slightly higher in PaO₂/FiO₂/RR than that for the ROX index (0.74 vs. 0.71, *p* = 0.02).




Discussion

To the best of our knowledge, this is the largest study to explore the ROX index as a predictor for NIV failure in patients with de novo acute respiratory failure. The index had similar predictive power as PaO_2/FiO_2 . It had a similar distinguishing power to $PaO_2/FiO_2/RR$ in most cases. Three cutoff values (2, 6, and 10) were selected to classify patients into low, moderate, high, and very high risk for NIV failure.

The ROX index is mainly used to predict HFNC failure in patients with acute respiratory failure. In a classic study that focused on using the ROX index to predict HFNC failure, AUC was between 0.66 and 0.80 from initiation to 24 h HFNC [12]. In our study, AUC was similar, being between 0.64 and 0.77 for the prediction of NIV

failure using the ROX index. This indicates that the predictive power of the ROX index for treatment failure in NIV patients was the same as that in HFNC patients. It is worth noting that the AUC was 0.64 when the index was used to predict NIV failure before NIV. It is difficult to predict NIV failure using only the ROX index at this time point. A combination of other risk factors can improve the predictive power. Using a comprehensive assessment tool such as the HACOR or updated HACOR score is another strategy to improve predictive accuracy [10, 17].

PaO_2/FiO_2 is associated with NIV failure [27]. Patients with lower PaO_2/FiO_2 values are more likely to experience NIV failure. It requires an arterial blood gas test to calculate PaO_2/FiO_2 . However, this test is invasive and painful for patients. In addition, it is inconvenient



to perform frequently. In contrast, measurement of the ROX index is noninvasive and can be performed at any time. Our study shows that the predictive power of the index for predicting NIV failure was similar to that of PaO_2/FiO_2 . Therefore, ROX index can be served as an alternative method to predict NIV failure at any time.

Delayed intubation in NIV patients is associated with increased mortality [8, 9]. However, it is difficult to

balance unnecessary and delayed intubation. The ROX index is a feasible assessment tool for predicting NIV failure at the bedside. It can be used to aid in decision-making, as it can stratify patients into low, moderate, high, and very high risk for NIV failure groups. In patients at high risk for NIV failure, NIV should be used cautiously. In those with very high risk for NIV failure, early intubation may be the best choice.




Table 2 Predictive power of NIV failure tested by different ROX index

Cutoff value	Probability of NIV failure (%)	Sensitivity (%)	Specificity (%)
After 1–2 h NIV, N = 1286			
2	75	100	2.1
4	65	95.0	24.3
6	50	75.9	56.7
8	37	45.7	79.6
10	25	22.8	91.4
After 12 h NIV, N = 1068			
2	79	100	1.4
4	67	97.9	19.5
6	53	85.7	48.6
8	37	61.5	71.6
10	24	33.7	88.5
After 24 h NIV, N = 911			
2	82	99.8	1.2
4	69	98.1	24.9
6	52	87.4	50.2
8	35	64.5	76.9
10	21	38.6	88.6

NIV noninvasive ventilation, ROX ratio of SpO₂/FiO₂ to respiratory rate

This study had several limitations. First, we only reported the ROX index within 24 h NIV. The predictive power of the index for use of NIV exceeding 24 h was not identified. Second, the use of NIV is a continuous process. Clinicians should assess the ROX index dynamically to avoid delayed intubation. Third, some physicians in this study may have used the ROX index in some patients at some point. This may have influenced their decision regarding intubation. As we did not record this issue, we are unable to report these data. Fourth, we only enrolled patients with de novo acute

respiratory failure, due to the lack of clear evidence on the use of NIV in this population as recommended by the ERS/ATS guideline [18]. The index’s predictive power for NIV failure in other populations is unclear.

Conclusions

The ROX index is convenient and reproducible. It has moderate power for predicting NIV failure in patients with de novo acute respiratory failure. Assessment of the ROX index at the bedside is encouraged when NIV is used.

Table 3 Comparisons in predictive power between ROX index, PaO₂/FiO₂, and PaO₂/FiO₂/RR

	AUC (95% CI)	p ^a	p ^b
Before NIV			
ROX index	0.64 (0.61–0.67)	0.10	0.47
PaO ₂ /FiO ₂	0.61 (0.58–0.64)		
PaO ₂ /FiO ₂ /RR	0.65 (0.62–0.67)		
After 1–2 h NIV			
ROX index	0.71 (0.68–0.74)	0.84	0.02
PaO ₂ /FiO ₂	0.71 (0.68–0.73)		
PaO ₂ /FiO ₂ /RR	0.74 (0.71–0.76)		
After 12 h NIV			
ROX index	0.74 (0.71–0.77)	0.14	0.41
PaO ₂ /FiO ₂	0.72 (0.69–0.74)		
PaO ₂ /FiO ₂ /RR	0.75 (0.73–0.78)		
After 24 h NIV			
ROX index	0.77 (0.74–0.80)	0.26	0.47
PaO ₂ /FiO ₂	0.75 (0.72–0.78)		
PaO ₂ /FiO ₂ /RR	0.78 (0.75–0.81)		

NIV noninvasive ventilation, ROX ratio of SpO₂/FiO₂ to respiratory rate, AUC area under the receiver operating characteristics curve, CI confidence interval, RR respiratory rate

^a ROX index vs. PaO₂/FiO₂

^b ROX index vs. PaO₂/FiO₂/RR

Abbreviations

ROX: SpO₂/FiO₂ to respiratory rate; NIV: Noninvasive ventilation; AUC: Area under the receiver operating characteristic curve; HACOR: Heart rate, acidosis, consciousness, oxygenation, and respiratory rate; OR: Odds ratio; CI: Confidence interval; HFNC: High-flow nasal cannula; ARDS: Acute respiratory distress syndrome; SOFA: Sequential organ failure assessment; CT: Computed tomographic; ICU: Intensive care unit; GCS: Glasgow coma scale; RR: Respiratory rate.

Acknowledgements

We thank all the staff members in participating centers to help in data collection.

Author contributions

FY conceived the study and took responsibility for the integrity of the study. JD and JY joined in study design, data analysis, data interpretation, and manuscript preparation. LJ, LB, WH, WS and KW joined in patient screening, data collection, data management, data interpretation, and revised the manuscript. All authors contributed to the intellectual content of the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The data set used and/or analyzed during the current study is available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate

The study protocol was approved by local ethics committee. Informed consent was obtained from patients or their family members. The study was performed in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

We declare that we have no competing interests.

Author details

¹Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. ²Department of Respiratory and Critical Care Medicine, The Chongqing Western Hospital, Chongqing 400051, China. ³Department of Critical Care Medicine, Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160, China. ⁴Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. ⁵Department of ICU, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W. Sec 2, 1st Ring Rd, Chengdu 610072, China.

Received: 22 August 2022 Accepted: 23 November 2022

Published online: 05 December 2022

References

- Ozsancak Ugurlu A, Sidhom SS, Khodabandeh A, et al. Use and outcomes of noninvasive positive pressure ventilation in acute care hospitals in Massachusetts. *Chest*. 2014;145:964–71.
- Zayed Y, Barbarawi M, Kheiri B, et al. Initial noninvasive oxygenation strategies in subjects with de novo acute hypoxemic respiratory failure. *Respir Care*. 2019;64:1433–44.
- Tonelli R, Fantini R, Tabbi L, et al. Early inspiratory effort assessment by esophageal manometry predicts noninvasive ventilation outcome in de novo respiratory failure. A pilot study. *Am J Respir Crit Care Med*. 2020;202:558–67.
- Carteaux G, Millán-Guilarte T, De Prost N, et al. Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume. *Crit Care Med*. 2016;44:282–90.
- Mercurio G, D'Arrigo S, Moroni R, et al. Diaphragm thickening fraction predicts noninvasive ventilation outcome: a preliminary physiological study. *Crit Care*. 2021;25:219.

6. Koga Y, Kaneda K, Fujii N, et al. Association between increased nonaerated lung weight and treatment failure in patients with de novo acute respiratory failure: difference between high-flow nasal oxygen therapy and noninvasive ventilation in a multicentre retrospective study. *J Crit Care*. 2021;65:221–5.
7. Azoulay E, Pickkers P, Soares M, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efrain multinational prospective cohort study. *Intensive Care Med*. 2017;43:1808–19.
8. Bai L, Ding F, Xiong W, et al. Early assessment of the efficacy of non-invasive ventilation tested by HACOR score to avoid delayed intubation in patients with moderate to severe ARDS. *Ther Adv Respir Dis*. 2022;16:17534666221081042.
9. Carrillo A, Gonzalez-Diaz G, Ferrer M, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. *Intensive Care Med*. 2012;38:458–66.
10. Duan J, Han X, Bai L, et al. Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients. *Intensive Care Med*. 2017;43:192–9.
11. Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. *J Crit Care*. 2016;35:200–5.
12. Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. *Am J Respir Crit Care Med*. 2019;199:1368–76.
13. Duan J, Zeng J, Deng P, et al. High-flow nasal cannula for COVID-19 patients: a multicenter retrospective study in China. *Front Mol Biosci*. 2021;8: 639100.
14. Kim JH, Baek AR, Lee SI, et al. ROX index and SpO₂/FIO₂ ratio for predicting high-flow nasal cannula failure in hypoxemic COVID-19 patients: a multicenter retrospective study. *PLoS ONE*. 2022;17: e0268431.
15. Junhai Z, Jing Y, Beibei C, et al. The value of ROX index in predicting the outcome of high flow nasal cannula: a systematic review and meta-analysis. *Respir Res*. 2022;23:33.
16. Zhou X, Liu J, Pan J, et al. The ROX index as a predictor of high-flow nasal cannula outcome in pneumonia patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. *BMC Pulm Med*. 2022;22:121.
17. Duan J, Chen L, Liu X, et al. An updated HACOR score for predicting the failure of noninvasive ventilation: a multicenter prospective observational study. *Crit Care*. 2022;26:196.
18. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2017. <https://doi.org/10.1183/13993003.02426-2016>.
19. Branson RD, Hess DR, Chatburn RL. *Respiratory care equipment*. Philadelphia: J.B. Lippincott Company; 1995. p. 55–62.
20. Wang K, Zhao W, Li J, et al. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing. *China Ann Intensive Care*. 2020;10:37.
21. Liu J, Duan J, Bai L, et al. Noninvasive ventilation intolerance: characteristics, predictors, and outcomes. *Respir Care*. 2016;61:277–84.
22. Levy ML, Le Jeune I, Woodhead MA, et al. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. *Prim Care Respir J*. 2010;19:21–7.
23. Shu W, Guo S, Yang F, et al. Association between ARDS etiology and risk of noninvasive ventilation failure. *Ann Am Thorac Soc*. 2022;19:255–63.
24. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. *JAMA*. 2012;307:2526–33.
25. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. *Radiology*. 1983;148:839–43.
26. Confalonieri M, Garuti G, Cattaruzza MS, et al. A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation. *Eur Respir J*. 2005;25:348–55.
27. Antonelli M, Conti G, Esquinas A, et al. A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. *Crit Care Med*. 2007;35:18–25.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
